FDA Grants Priority Review to Fetroja Therapy for HAP/VAP

The FDA has accepted a supplemental NDA for Fetroja, which is intended to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.